MET and familial pancreatic carcinoma: O-CMC-MET NPs can achieve a sustained release effect through the pH-dependent drug release, prolong the drug retention time in blood/circulation, and have blood compatibility; although it is nonspecific, due to the inhibition of mTOR activity in MiaPaCa-2 cells mediated by MET, the NPs showed a dose-dependent preferential toxicity to pancreatic cancer cells compared with normal cells (Snima et al., 2012).